LT2842573T - Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2 - Google Patents

Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2

Info

Publication number
LT2842573T
LT2842573T LTEP14188785.1T LT14188785T LT2842573T LT 2842573 T LT2842573 T LT 2842573T LT 14188785 T LT14188785 T LT 14188785T LT 2842573 T LT2842573 T LT 2842573T
Authority
LT
Lithuania
Prior art keywords
growth factor
monoclonal antibodies
factor receptor
fibroblast growth
fibroblast
Prior art date
Application number
LTEP14188785.1T
Other languages
English (en)
Inventor
Kyung Jin Kim
Wei-Meng Zhao
Hangil Park
Original Assignee
Galaxy Biotech, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech, Llc filed Critical Galaxy Biotech, Llc
Publication of LT2842573T publication Critical patent/LT2842573T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
LTEP14188785.1T 2008-11-07 2009-11-06 Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2 LT2842573T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
LT2842573T true LT2842573T (lt) 2017-12-11

Family

ID=42153600

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14188785.1T LT2842573T (lt) 2008-11-07 2009-11-06 Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2
LTEP17191118.3T LT3290052T (lt) 2008-11-07 2009-11-06 Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17191118.3T LT3290052T (lt) 2008-11-07 2009-11-06 Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2

Country Status (21)

Country Link
US (8) US8101723B2 (lt)
EP (4) EP3783024A1 (lt)
JP (7) JP5627591B2 (lt)
KR (1) KR101699432B1 (lt)
CN (1) CN102131524B (lt)
AU (1) AU2009313357B2 (lt)
BR (1) BRPI0917315B8 (lt)
CA (2) CA2733668C (lt)
DK (3) DK3290052T3 (lt)
ES (3) ES2770134T3 (lt)
HK (3) HK1160012A1 (lt)
HR (2) HRP20171640T1 (lt)
HU (1) HUE035700T2 (lt)
LT (2) LT2842573T (lt)
MX (1) MX2011000455A (lt)
NO (1) NO2842573T3 (lt)
PL (3) PL3290052T3 (lt)
PT (3) PT2365828E (lt)
RU (1) RU2546254C9 (lt)
SI (2) SI3290052T1 (lt)
WO (1) WO2010054265A2 (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
PT2365828E (pt) 2008-11-07 2014-12-12 Galaxy Biotech Llc Anticorpos monoclonais para o receptor 2 do factor de crescimento de fibroblastos
RU2012153241A (ru) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
JP2015505850A (ja) 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
JP6188681B2 (ja) * 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JP6488236B2 (ja) * 2012-12-21 2019-03-20 ヤンセン バイオテツク，インコーポレーテツド 可溶型線維芽細胞増殖因子受容体の高感度多重イムノアッセイ
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
RS58719B1 (sr) * 2013-08-01 2019-06-28 Five Prime Therapeutics Inc Nefukozilisana anti-fgfr2iiib antitela
WO2015053407A1 (ja) * 2013-10-08 2015-04-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
WO2016163433A1 (ja) * 2015-04-08 2016-10-13 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
SG11201804134YA (en) * 2015-11-23 2018-06-28 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
KR20200006538A (ko) 2017-05-16 2020-01-20 파이브 프라임 테라퓨틱스, 인크. 암 치료에서 화학요법제와 병용되는 항-fgfr2 항체
TWI811220B (zh) 2017-06-02 2023-08-11 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
TW201922782A (zh) 2017-10-24 2019-06-16 美商麥珍塔治療學股份有限公司 去除cd117+細胞之組合物及方法
SG11202003280SA (en) 2017-10-24 2020-05-28 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
CN112804989A (zh) 2018-10-05 2021-05-14 戊瑞治疗有限公司 抗fgfr2抗体制剂
CA3160812A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
WO2022143728A1 (zh) * 2020-12-29 2022-07-07 深圳福沃药业有限公司 抗fgfr2抗体及其用途
WO2023056916A1 (zh) * 2021-10-08 2023-04-13 深圳福沃药业有限公司 Adcc增强型抗fgfr2抗体及其用途
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0481000B1 (en) * 1989-07-06 1999-05-12 The Regents Of The University Of California Receptors for fibroblast growth factors
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7531304B2 (en) 2002-01-31 2009-05-12 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for screening FGFR-4 agonists
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AU2004312376A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1773305A2 (en) * 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP2009536834A (ja) * 2006-05-12 2009-10-22 ジェネンテック・インコーポレーテッド 癌の診断及び治療のための方法及び組成物
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
CA2668295A1 (en) * 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
JP2010525301A (ja) * 2007-03-23 2010-07-22 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 子宮内膜癌および前癌の診断、分類および治療の方法
EP2205277B1 (en) 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
PT2365828E (pt) 2008-11-07 2014-12-12 Galaxy Biotech Llc Anticorpos monoclonais para o receptor 2 do factor de crescimento de fibroblastos
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
US20100196364A1 (en) 2010-08-05
CA3166399A1 (en) 2010-05-14
JP5627591B2 (ja) 2014-11-19
JP2023116746A (ja) 2023-08-22
US9834609B2 (en) 2017-12-05
JP7301106B2 (ja) 2023-06-30
US8603987B2 (en) 2013-12-10
JP2014240385A (ja) 2014-12-25
US20180094063A1 (en) 2018-04-05
KR20110081141A (ko) 2011-07-13
EP2842573A1 (en) 2015-03-04
US10689448B2 (en) 2020-06-23
DK2842573T3 (en) 2017-10-30
ES2770134T3 (es) 2020-06-30
EP2365828B1 (en) 2014-10-15
HK1160012A1 (en) 2012-08-10
HK1207974A1 (en) 2016-02-19
JP2019052165A (ja) 2019-04-04
EP3290052B1 (en) 2019-12-25
SI2842573T1 (en) 2018-01-31
PL2365828T3 (pl) 2015-04-30
KR101699432B1 (ko) 2017-01-24
EP3290052A1 (en) 2018-03-07
WO2010054265A2 (en) 2010-05-14
BRPI0917315B1 (pt) 2020-12-08
PL2842573T3 (pl) 2018-04-30
DK3290052T3 (da) 2020-02-03
CA2733668C (en) 2022-08-30
JP6342223B2 (ja) 2018-06-13
US8101723B2 (en) 2012-01-24
WO2010054265A3 (en) 2010-09-16
ES2523740T3 (es) 2014-12-01
JP2017019807A (ja) 2017-01-26
DK2365828T3 (en) 2014-12-08
JP6445496B2 (ja) 2018-12-26
US20200347141A1 (en) 2020-11-05
PT2365828E (pt) 2014-12-12
JP2022008996A (ja) 2022-01-14
RU2546254C2 (ru) 2015-04-10
HRP20171640T1 (hr) 2018-01-12
BRPI0917315A2 (pt) 2015-11-17
SI3290052T1 (sl) 2020-07-31
ES2646168T3 (es) 2017-12-12
US9382324B2 (en) 2016-07-05
NO2842573T3 (lt) 2018-02-24
JP2012508184A (ja) 2012-04-05
BRPI0917315B8 (pt) 2021-05-25
JP6661734B2 (ja) 2020-03-11
CA2733668A1 (en) 2010-05-14
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
US20160362496A1 (en) 2016-12-15
LT3290052T (lt) 2020-02-25
HK1249053A1 (zh) 2018-10-26
US10138301B2 (en) 2018-11-27
JP2020096615A (ja) 2020-06-25
EP3783024A1 (en) 2021-02-24
AU2009313357A1 (en) 2010-05-14
CN102131524A (zh) 2011-07-20
HRP20200090T1 (hr) 2020-04-03
PL3290052T3 (pl) 2020-06-29
US20120134994A1 (en) 2012-05-31
HUE035700T2 (en) 2018-05-28
EP2365828A4 (en) 2012-06-06
CN102131524B (zh) 2014-05-14
JP6960485B2 (ja) 2021-11-05
US20190153105A1 (en) 2019-05-23
PT3290052T (pt) 2020-02-06
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
US20230242650A1 (en) 2023-08-03
EP2365828A2 (en) 2011-09-21
AU2009313357B2 (en) 2015-06-11
US20140193899A1 (en) 2014-07-10
EP2842573B1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
HK1249053A1 (zh) 成纖維細胞生長因子受體2的單克隆抗體
HK1197252A1 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
ZA201100301B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ZA200807903B (en) Humanized monoclonal antibodies to hepatocyte growth factor
EP2288717A4 (en) MONOCLONAL ANTIBODIES AGAINST bFGF
EP2331579A4 (en) MONOCLONAL ANTIBODIES
HK1138790A1 (en) Anti-sclerostin antibodies
SI2195026T1 (sl) Protitelesa proti sklerostinu
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2483309A4 (en) ANTIBODIES BINDING SPECIFICALLY TO THE EPIDERMAL GROWTH FACTOR RECEPTOR
PL2121758T3 (pl) Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści
ZA200905341B (en) Recombinant anti-epidermal growth factor receptor antibody compositions